Takeda in Velcade patent blow
August 25, 2015Manufacturing and Production Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib
Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that …
AZ appoints Genentech’s Sean Bohen as chief medical officer
August 25, 2015Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Briggs Morrison, Sean Bohen
AstraZeneca has appointed Dr Sean Bohen as executive vice president of global medicines development and chief medical officer.Dr Bohen will …
Clinical Trial Transparency – A Personal View
August 24, 2015Research and Development ABPI, PMCPA, clinical trial transparency, clinical trials, health research authority, transparency
During the time I worked as research, medical and innovation director at the ABPI, between October 2012 and January 2015, …
AstraZeneca cancer drug trialled for pancreatic cancer
August 24, 2015Research and Development
AstraZeneca is working with the Banner MD Anderson Cancer Center in Arizona to test its cancer drug Lynparza as a …
AstraZeneca and Peregrine in immuno-oncology collaboration
August 24, 2015Research and Development AstraZeneca, Cancer, MEDI4736, Peregrine, Peregrine Pharmaceuticals, bavituximab, durvalumab, immunoncology, immunotherapy, oncology, tumours
AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …
Doctors ‘face jail over pharma payments’
August 24, 2015Sales and Marketing ABPI, Jeremy Hunt, NHS, PMCPA, bribery, doctor payments, health secretary, transparency
Healthcare professionals who have inappropriate financial links with pharma companies will face prosecution and up to 10 years in jail, …
Takeda gets European MAA approval for ixazomib
August 21, 2015Medical Communications, Research and Development (FDA/EMA/MHRA), FDA/EMA/MHRA, Takeda, ixazomib, multiple myeloma
Takeda has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for ixazomib, an investigational …
Novartis buys rights to GSK MS drug for up to $1 billion
August 21, 2015Medical Communications, Research and Development, Sales and Marketing GlaxoSmithKline, Novartis, multiple sclerosis, ofatumumab
Novartis has added to its burgeoning multiple sclerosis portfolio with the $300 million acquisition of all outstanding rights to GlaxoSmithKline’s …
Lilly and Boehringer’s Jardiance diabetes drug reduces cardiovascular risks
August 21, 2015Medical Communications, Research and Development Boehringer Ingelheim, Eli Lilly, diabetes drugs
Eli Lilly’s diabetes drug Jardiance (empagliflozin) has shown in a study to be the very first blood sugar lowering drug …
Sun Pharma gets FDA approval for acne treatment
August 21, 2015Medical Communications, Research and Development, Sales and Marketing Sun Pharma. acne treatments, drug approvals
The FDA has approved Sun Pharma’s new acne treatment, Ximino.The Ximino (minocycline hydrochloride) extended-release capsules, which will be available in …
Horizon Pharma receives third rejection from Depomed
August 21, 2015Sales and Marketing Depomed, Horizon Pharma, pharma mergers and acquisitions
Depomed has announced that its board has unanimously rejected Horizon Pharma’s third proposal to buy the California-based company. Following its …
Monique Levy joins Google’s healthcare advisory board
August 20, 2015Medical Communications google
Monique Levy, vice president of digital innovation at healthcare data and analytics firm Decision Resources Group, is joining Google’s healthcare …
FDA hits Mylan’s Indian plants with warning letter
August 20, 2015Manufacturing and Production Contamination, FDA, Mylan, Pfizer, manufacturing, production
The FDA has served Mylan with a warning letter citing contamination at three of its manufacturing facilities in India. Inspections …
Novartis and Merck skin cancer drugs move through pipeline
August 20, 2015Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib
Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …
Valeant confirms $1bn deal for ‘female viagra’ creator Sprout
August 20, 2015Manufacturing and Production, Sales and Marketing Addyi, Sprout, Sprout Pharma, Sprout Pharmaceuticals, Valeant, flibanserin
Canada’s Valeant Pharmaceuticals has confirmed it will pay $1 billion to acquire Sprout Pharmaceuticals, the company behind the female libido …
Lundbeck sheds 1,000 jobs in £284 million restructure
August 20, 2015Manufacturing and Production, Sales and Marketing Lundbeck, generics, job losses, patents, redundancies, restructure, restructuring
Lundbeck is cutting a thousand jobs globally as part of a restructuring programme to significantly lower its cost and focus …
Amgen agrees to $71m settlement over false advertising
August 19, 2015Sales and Marketing Amgen, Aranesp, Enbrel
Amgen has reached a $71 million settlement with 48 US states and the District of Columbia, to resolve allegations that …
FDA approves ‘female viagra’
August 19, 2015Research and Development, Sales and Marketing Addyi, FDA, HSDD, Sprout, Sprout Pharmaceuticals, flibanserin, hypoactive sexual desire disorder
The FDA has approved Sprout Pharmaceuticals’ Addyi, a controversial libido-enhancing drug for women that has been dubbed the ‘female viagra’. …
Nottingham receives go ahead for new £30m life science facility
August 19, 2015Manufacturing and Production, Research and Development BioCity Nottingham, R&D
Hundreds of pharma jobs are expected to be created in Nottingham after the construction of a new £30 million life …
Confronting the ‘danger’ of blocking progress on clinical trial transparency
August 19, 2015Research and Development EMIG, Ethical Medicines Industry Group, Richmond Pharmacology, clinical trial registration, clinical trial transparency, health research authority, hra, sense about science, transparency
The Ethical Medicines Industry Group and Sense About Science – a co-founder of the ALLTrials campaign – have written a …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
